SCHOTT will showcase its extensive line of TopPac polymer syringes at Pharmapack North America in New York on June 10-12, 2014 at booth #3466. The broad range of applications for TopPac syringes helps medical practitioners address the two main concerns of the health care sector: ensuring patient comfort and safety.
TopPac syringes have been optimized for injecting highly viscous drugs, such as hyaluronic acid (HA), and for intensive care, including infusion therapy with large volume syringes via infusion pumps. In both of these applications, TopPac offers maximized precision, safety, and comfort, ensuring high-quality patient care through safe and comfortable drug delivery.
One example of a highly viscous injectable drug is HA, a natural, biodegradable substance that occurs in the human body. The injectable form of HA is primarily administered in pre-filled syringes for three medical applications: cataract surgeries, when the substance is injected to expand the anterior chamber of the eyeball; osteoarthritis, when hyaluronic acid lubricates joints during movement; and as a dermal filler, when the acid is injected into the skin to reduce wrinkles, fine lines, and scars.
Due to its high viscosity, HA requires a greater amount of pressure to inject the substance than a typical syringe-based medication. This can cause discomfort for both patients and healthcare workers. SCHOTT TopPac® syringes are specifically designed to counteract these effects, as the barrel is treated with cross-linked silicone to reduce injection forces and improve administration accuracy. Additionally, TopPac’s integrated luer-lock retains tight needle connectivity with ultra-thin needles (30 / 31 gauge), eliminating leakage and needle ejection.
The syringes also offer a solution to medications and anesthetics administered via infusion pumps. Practitioners often have zero room for error as the right concentration, dose, and delivery can significantly impact patient safety.
TopPac syringes reduce the chance of human administration errors, as they are pre-filled with accurate doses of medication. The luer-lock system guarantees a leak-proof connection between the syringe and the intravenous line to ensure accurate administration for infusion therapy. The system design and the syringe barrel, treated with cross-linked silicone, provide optimized gliding characteristics to be compatible with pump systems.
The product is available in small 1 to 5 milliliter (ml) and large 10, 20, 50 ml formats to be used in combination with syringe pumps for intensive care. It’s made of cyclic olefin copolymer (COC), which makes it break resistant, lightweight, and helps it retain a transparent, glass-like appearance. The syringes are manufactured in fully integrated, clean-room production environments that ensure low contamination and particle levels without washing. TopPac syringes are sterilized by irradiation and are suitable for terminal sterilization with steam.
“TopPac pre-fillable syringes are designed to support a wide range of applications while also reducing total cost of ownership for pharmaceutical companies and health care facilities,” said Anil Busimi, Head of Global Product Management Syringe Business at SCHOTT. “TopPac syringes’ familiar nest and tub configurations make them easy to integrate into existing filling lines. Their highly durable bodies reduce the chances of breakage. By making TopPac syringes more versatile and cost-effective for pharmaceutical manufacturers, we’re enabling their use in a number of procedures, improving accuracy, comfort, and safety for countless patients.”
SCHOTT (schott.com) is an international technology group with 130 years of experience in the areas of specialty glass and materials and advanced technologies. SCHOTT ranks number one in the world with many of its products. Its core markets are the household appliance, pharmaceutical, electronics, optics and transportation industries. The company is strongly committed to contributing to its customers’ success and making SCHOTT an important part of people’s lives with high-quality products and intelligent solutions. SCHOTT is committed to managing its business in a sustainable manner and supporting its employees, society and the environment. The SCHOTT Group maintains close proximity to its customers with manufacturing and sales units in 35 countries. Its workforce of 15,400 employees generated worldwide sales of US$ 2.5 billion for the 2012/2013 fiscal year.
Press contact: Mike Lizun - Gregory FCA on behalf of SCHOTT
P: 610-642-1435 - E: mike[.]gregoryfca.com.